When was Cellbricks Therapeutics founded?

Cellbricks Therapeutics was founded in 2016 and raised its 1st funding round 10 years after it was founded.

Where is Cellbricks Therapeutics located?

Cellbricks Therapeutics is headquartered in Berlin, Germany.

Who is the current CEO of Cellbricks Therapeutics?

Simon MacKenzie of Cellbricks Therapeutics.

Which legal entities is Cellbricks Therapeutics associated with?

Cellbricks Therapeutics is associated with Cellbricks GmbH and 2 others.

How many employees does Cellbricks Therapeutics have?

As of Jul 31, 2026, the latest employee count at Cellbricks Therapeutics is 29.

Is Cellbricks Therapeutics a funded company?

Cellbricks Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 25, 2026.

When was the latest funding round of Cellbricks Therapeutics?

Cellbricks Therapeutics' latest funding was a $***** Seed round on Mar 25, 2026, with participation from 3 investors. Its primary sector is Regenerative Medicine. Globally, the Regenerative Medicine sector has seen $109M in funding in 2026 to date.

Where does Cellbricks Therapeutics rank among its competitors?

Cellbricks Therapeutics ranks 28th amongst 142 active competitors, of which 36 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Cellbricks Therapeutics, which secured $8.11M in Mar, 2026.

Who are the top competitors of Cellbricks Therapeutics?

Cellbricks Therapeutics' top competitors include Tenaya Therapeutics, RevBio and Orca Bio. Among them, Cellbricks Therapeutics secured the most recent funding round in March, 2026.

Cellbricks Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of implantable tissue therapeutics using biofabrication. This company develops and produces implantable tissue therapeutics to address the limitations of current injectable cell therapies. The approach involves combining therapeutic cells with biomaterials through a proprietary light-based bioprinting platform. The resulting implantable tissues are designed to be biologically functional, immune-compatible, and optimized for surgical implantation, leading to sustainable therapeutic effects. The technology enables the creation of vascularized, complex tissue at scale.

Website: cellbricks-therapeutics.com
Social
Phone Number: +49 **********

Key Metrics

Founded Year

2016

Location

Berlin, Germany

Stage

Seed

Total Funding

$8.11M in 1 round

Latest Funding Round

Seed, Mar 25, 2026, $*****

Investors

Silicon Roundabout Ventures & 4 more

Ranked

28^th among 142 active competitors

Employee Count

29 as on Jul 31, 2026

Similar Companies

Tenaya Therapeutics & 175 more

View Cellbricks Therapeutics' full profile

Cellbricks Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cellbricks Therapeutics Inc CIN: 10001367 , United States, Active	Nov 08, 2024	-	-	-
Cellbricks GmbH CIN: HRB179568 , Germany, Active	Aug 24, 2016	-	-
Cellbricks Gmbh CIN: F1103_HRB179568B , Germany, Active	Aug 25, 2016	-	23 (As on Dec 31, 2023)

Cellbricks Therapeutics has raised a total funding of $8.11M over 1 round. Its latest funding round was a Seed round on Mar 25, 2026 for $*****. 3 investors participated in its latest round. Cellbricks Therapeutics has 5 institutional investors.

Here is the list of recent funding rounds of Cellbricks Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 25, 2026	9868376	Seed	7034257	2022515	8958245	5710227

Access funding benchmarks and valuations. Sign up today!

View details of Cellbricks Therapeutics's funding rounds and investors

The founders of Cellbricks Therapeutics are Alexander Thomas, Tobias Lam and Lutz Kloke. Alexander Leutner and Simon MacKenzie are the CEOs of Cellbricks Therapeutics.

Here are the details of Cellbricks Therapeutics' key team members:

Alexander Thomas: Co-Founder of Cellbricks Therapeutics.
Contact Info: 1 email address
Tobias Lam: Co-Founder & CTO of Cellbricks Therapeutics.
Contact Info: 1 email address
Lutz Kloke: Former Co-Founder of Cellbricks Therapeutics.
Simon MacKenzie: Co-CEO of Cellbricks Therapeutics.
Contact Info: 1 email address

View details of Cellbricks Therapeutics's Founder profiles and Board Members

Cellbricks Therapeutics' employee count trend

Cellbricks Therapeutics has 29 employees as of Jul 26. Here is Cellbricks Therapeutics's employee count trend over the years:

Employee count trend for Cellbricks Therapeutics

Uncover Cellbricks Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellbricks Therapeutics include Tenaya Therapeutics, RevBio and Orca Bio. Here is the list of Top 10 competitors of Cellbricks Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
2nd	RevBio 2014, Lowell (United States), Series B	Developer of synthetic adhesive used for bone/dental repair	$27.5M	Pacific Dental Services, MassChallenge & 4 others	63/100
3rd	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	63/100
4th	Tune Therapeutics 2009, Seattle (United States), Series B	Developer of cell and gene therapy by using the epigenomic platform	$222M	New Enterprise Associates, Emerson Collective ... & 9 others	63/100
5th	LIfT Biosciences 2016, London (United Kingdom), Series A	Developer of neutrophil-based cell therapies for solid tumors	$20.1M	Kizoo, Downing & 13 others	61/100
6th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	61/100
7th	Avita Medical 1992, Cambridge (United Kingdom), Public	Regenerative and Respiratory Medicine product company	-	BioScience Managers, Orbimed & 6 others	59/100
8th	Orthofix 1980, Lewisville (United States), Public	Developer of reconstructive and regenerative solutions for bone-related conditions	-	-	59/100
9th	Organogenesis 1985, Canton (United States), Public	Regenerative tissue innovations for advanced wound care and surgical solutions	$30M	Spring St. Group, Eastward Capital Partners ... & 2 others	59/100
10th	LambdaVision 2009, Farmington (United States), Public	Provider of a protein-based retinal prosthesis for retinal degenerative diseases	$7.65M	Seven Seven Six, Aurelia Foundry & 9 others	57/100
28th	Cellbricks Therapeutics 2016, Berlin (Germany), Seed	Developer of implantable tissue therapeutics using biofabrication	$8.11M	Silicon Roundabout Ventures, Brooks Hill Partners ... & 3 others	43/100